Emerging antifungal agents in human medicine: Mechanisms, clinical progress, and future perspectives. (PubMed, Eur J Med Chem) - Aug 6, 2026 - "This narrative review summarizes the current landscape of emerging antifungal therapies, focusing on ibrexafungerp 1, rezafungin 2, fosmanogepix 3, olorofim 4, opelconazole 5, and oteseconazole 6. However, important challenges remain, including limited activity against Mucorales for several agents, the potential emergence of future resistance, and the need for additional comparative clinical data and real-world experience. Overall, the expanding antifungal pipeline represents a major advancement toward more targeted and individualized antifungal therapy and may significantly reshape the future management of invasive and refractory fungal infections."
Journal • Review • Candidiasis • Infectious Disease • Pulmonary Disease • Respiratory Diseases
|
|
Abbas Khan; Abdelali Agouni; Alaa Farhan; Ameera Al-Jabiry; Basma Hanbali; Mohanad Shkoor; Raed M Al-Zoubi; Sally R Al-Zoubi; Yosef R Al-Zoubi
|